SCICLONE PHARMACEUTICALS (HOLDINGS) LIMITED |
Delayed
Other stock markets
|
5-day change | 1st Jan Change | ||
| 18 HKD | +0.11% |
|
-0.11% | +29.17% |
| Apr. 18 | Sciclone Pharmaceuticals to Dispatch Privatization Documents by May 31 | MT |
| Apr. 01 | SciClone Pharmaceuticals Logs 31% Increase in 2023 Profit | MT |
| Sales 2023 | 3.16B 436M 3.41B | Sales 2024 * | 3.61B 498M 3.9B | Capitalization | 10.14B 1.4B 10.96B |
|---|---|---|---|---|---|
| Net income 2023 | 1.12B 155M 1.21B | Net income 2024 * | 1.15B 159M 1.24B | EV / Sales 2023 | 2.44 x |
| Net cash position 2023 * | 1.3B 179M 1.4B | Net cash position 2024 * | 2.6B 358M 2.8B | EV / Sales 2024 * | 2.09 x |
| P/E ratio 2023 |
7.36
x | P/E ratio 2024 * |
9.4
x | Employees | 860 |
| Yield 2023 * |
2.25% | Yield 2024 * |
1.32% | Free-Float | 54.06% |
More Fundamentals
* Assessed data
More news
More press releases
| 1 week | -0.11% | ||
| Current month | +12.09% | ||
| 1 month | +0.22% | ||
| 3 months | +61.11% | ||
| 6 months | +85.74% | ||
| Current year | +29.17% |
1 week
17.98
18.16
1 month
17.5018.28
Current year
10.2618.28
1 year
8.7518.28
3 years
5.6518.28
5 years
5.6519.38
10 years
5.6519.38
| Managers | Title | Age | Since |
|---|---|---|---|
Hong Zhao
CEO | Chief Executive Officer | 60 | 20-05-31 |
Rong Rong Pan
DFI | Director of Finance/CFO | 46 | - |
Mao Li
CTO | Chief Tech/Sci/R&D Officer | 66 | 22-06-12 |
| Members of the board | Title | Age | Since |
|---|---|---|---|
Daniel Vasella
BRD | Director/Board Member | 70 | 20-05-31 |
Hong Zhao
CEO | Chief Executive Officer | 60 | 20-05-31 |
Zhen Fu Li
CHM | Chairman | 59 | 20-05-31 |
| Name | Weight | AuM | 1st Jan change | Investor Rating |
|---|---|---|---|---|
| 1.52% | 4 M€ | -27.92% | ||
| 0.05% | 12 M€ | -16.71% | - |
| Date | Price | Change | Volume |
|---|---|---|---|
| 24-04-26 | 18 | +0.11% | 4 252 497 |
| 24-04-25 | 17.98 | 0.00% | 4,094,391 |
| 24-04-24 | 17.98 | -0.11% | 8,088,488 |
| 24-04-23 | 18 | +0.11% | 3,489,896 |
| 24-04-22 | 17.98 | -0.11% | 4,924,408 |
Delayed Quote Hong Kong S.E., April 26, 2024 at 03:59 am EDT
More quotes
SciClone Pharmaceuticals Holdings Ltd is a China-based biopharmaceutical company principally engaged in developing and commercializing a portfolio of marketed products as well as pipeline with potential in its focused therapeutic areas including oncology and severe infection. The Company primarily engages in the sales of its proprietary product, Zadaxin, its in-licensed products and promotion products on behalf of its business partners in China.
Sector
Pharmaceuticals
Calendar
2024-08-15
- Q2 2024 Earnings Release (Projected)
Trading Rating
Investor Rating
ESG Refinitiv
Sell
Buy
Mean consensus
OUTPERFORM
Number of Analysts
2
Last Close Price
16.64
CNY
Average target price
16.5
CNY
Spread / Average Target
-0.86%
EPS Revisions
Annual profits - Rate of surprise
| 1st Jan change | Capi. | |
|---|---|---|
| +29.17% | 1.4B | |
| -4.66% | 87.53B | |
| +2.63% | 40.42B | |
| -21.76% | 29.48B | |
| +55.51% | 25.43B | |
| -14.78% | 15.59B | |
| -18.49% | 11.49B | |
| -15.61% | 11.1B | |
| -44.02% | 11.3B | |
| +4.34% | 8.75B |
- Stock Market
- Equities
- 6600 Stock
